Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Medtronic
Merck
McKesson
Colorcon

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MUCINEX

See Plans and Pricing

« Back to Dashboard

505(b)(2) Clinical Trials for MUCINEX

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
OTC NCT00902707 Evaluating the Effect of Mucinex® 1200 mg on Mucociliary and Cough Clearance From the Human Lung Completed Reckitt Benckiser LLC Phase 1 2009-05-01 The purpose of this research study is to test the ability of Mucinex, an oral, over-the-counter, FDA approved expectorant) to stimulate the clearance of inhaled particles from the subject's lungs (called "mucociliary clearance"). The study will also monitor the metabolism of the drug by the subject's body.
OTC NCT00902707 Evaluating the Effect of Mucinex® 1200 mg on Mucociliary and Cough Clearance From the Human Lung Completed University of North Carolina, Chapel Hill Phase 1 2009-05-01 The purpose of this research study is to test the ability of Mucinex, an oral, over-the-counter, FDA approved expectorant) to stimulate the clearance of inhaled particles from the subject's lungs (called "mucociliary clearance"). The study will also monitor the metabolism of the drug by the subject's body.
OTC NCT01114581 Evaluating the Effect of Mucinex 1200mg on Mucociliary and Cough Clearance During an Acute Respiratory Infection Completed Reckitt Benckiser LLC Phase 2 2010-04-01 The purpose of this research study is to explore the mechanism of action of Mucinex, an oral, over-the-counter, FDA approved expectorant in patients with acute respiratory tract infections.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for MUCINEX

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00441246 Phase 4 Study - Mucinex D as Adjunct Therapy Completed Adams Respiratory Therapeutics Phase 4 2007-02-01 The objective of the study is to evaluate the safety and efficacy of Mucinex D tablets in providing symptom relief when administered as an adjunct to antibiotic therapy in patients with acute respiratory infection.
NCT00902707 Evaluating the Effect of Mucinex® 1200 mg on Mucociliary and Cough Clearance From the Human Lung Completed Reckitt Benckiser LLC Phase 1 2009-05-01 The purpose of this research study is to test the ability of Mucinex, an oral, over-the-counter, FDA approved expectorant) to stimulate the clearance of inhaled particles from the subject's lungs (called "mucociliary clearance"). The study will also monitor the metabolism of the drug by the subject's body.
NCT00902707 Evaluating the Effect of Mucinex® 1200 mg on Mucociliary and Cough Clearance From the Human Lung Completed University of North Carolina, Chapel Hill Phase 1 2009-05-01 The purpose of this research study is to test the ability of Mucinex, an oral, over-the-counter, FDA approved expectorant) to stimulate the clearance of inhaled particles from the subject's lungs (called "mucociliary clearance"). The study will also monitor the metabolism of the drug by the subject's body.
NCT01046136 Mucinex Exploratory Cold Study Completed Reckitt Benckiser LLC Phase 2 2009-12-01 This is an exploratory, multicenter, randomized, blinded, placebo-controlled study of Mucinex in patients with colds. Patients will receive 7 days of treatment with either Mucinex or placebo. The study will assess the effects of Mucinex on sputum and cold symptoms.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for MUCINEX

Condition Name

Condition Name for MUCINEX
Intervention Trials
Healthy Subjects 7
Acute Respiratory Infection 2
Healthy 1
Filamentary Keratitis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for MUCINEX
Intervention Trials
Respiratory Tract Infections 4
Infection 3
Communicable Diseases 2
Bronchitis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for MUCINEX

Trials by Country

Trials by Country for MUCINEX
Location Trials
United States 46
India 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for MUCINEX
Location Trials
North Carolina 4
Massachusetts 3
Nebraska 3
Utah 2
New Jersey 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for MUCINEX

Clinical Trial Phase

Clinical Trial Phase for MUCINEX
Clinical Trial Phase Trials
Phase 4 3
Phase 2/Phase 3 1
Phase 2 2
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for MUCINEX
Clinical Trial Phase Trials
Completed 14
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for MUCINEX

Sponsor Name

Sponsor Name for MUCINEX
Sponsor Trials
Reckitt Benckiser LLC 9
Reckitt Benckiser Inc. 3
Adams Respiratory Therapeutics 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for MUCINEX
Sponsor Trials
Industry 14
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Express Scripts
Boehringer Ingelheim
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.